Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

Medicine and Dentistry

• Sunitinib 100%
• Solid Malignant Neoplasm 50%
• Tumor Xenograft 40%
• In Vitro 20%
• Xenograft 20%
• Tumor Progression 20%
• Rhabdoid Tumor 20%
• Pediatrics 20%
• Neoplasm 10%
• Vasculotropin Receptor 10%
• Histology 10%
• IC50 10%
• Ganglioneuroblastoma 10%
• Growth Rate 10%
• Antineoplastic Activity 10%
• Cancer Inhibition 10%
• Feeding 10%
• Rhabdomyosarcoma 10%
• Platelet Derived Growth Factor Receptor 10%
• Antiangiogenic Activity 10%
• Tyrosine-Kinase Inhibitor 10%
• Ewing Sarcoma 10%
• Leukemia Cell Line 10%
• Therapeutic Procedure 10%
• Cell Line 10%
• Pediatric Cancer 10%
• Selectivity 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Sunitinib 100%
• Solid Malignant Neoplasm 50%
• Tumor Growth 20%
• Rhabdoid Tumor 20%
• Neoplasm 10%
• Vasculotropin Receptor 10%
• IC50 10%
• Platelet Derived Growth Factor Receptor 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Cancer Inhibition 10%
• Neuroblastoma 10%
• Rhabdomyosarcoma 10%
• Ewing Sarcoma 10%

Biochemistry, Genetics and Molecular Biology

• Sunitinib 100%
• Solid 50%
• Pediatrics 30%
• Mutation 10%
• IC50 10%
• Antineoplastic Activity 10%
• Growth Rate 10%
• Growth Inhibition 10%
• VEGF Receptors 10%
• Growth 10%
• Antiangiogenic Activity 10%
• Time 10%